Novo Nordisk falls after Metsera shareholders vote for Pfizer's offer

U.S.-listed shares of Danish drugmaker Novo Nordisk NOVOb.CO fall 2.2% to $49.1 premarket

Metsera MTSR.O shareholders approved Pfizer's PFE.N takeover offer worth up to $10 billion, allowing the U.S. pharma giant re-entry into the lucrative obesity treatment market after a fierce bidding war with Wegovy-maker Novo Nordisk

Novo on Saturday said it would not be making an increased offer

Up to last close, NVO down 41.6%, PFE down 2.5% YTD while MTSR shares have climbed more than threefold since their January IPO